Lipozyme

Quick links to important sections

Lipozyme

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipozyme

Property Description
Active ingredient Pancreatin, Ox-bile (Bile extract), Pepsin
Form Oral tablet (typically enteric-coated)
Pharmacological class Digestive enzyme supplement, Cholagogue
Common use Supporting the breakdown of fats, proteins, and starches
Origin Derived biological/natural compound

What Type of Medicine is Lipozyme?

Lipozyme is a combination pharmaceutical preparation that belongs to the pharmacological class of digestive enzyme supplements and is also classified as a cholagogue. It is fundamentally a multi-component enzyme therapy designed to provide essential support when the body's natural digestive function is compromised. In this context, enzyme supplements play a key role in replacing biological activity that the body is unable to provide naturally. This formulation is distinctive because it integrates enzymes from both gastric and pancreatic origin, classifying it as a synergistic compound, rather than a single-ingredient replacement product like simple Pancrelipase preparations.


Composition: What Active Ingredients are in Lipozyme?

Lipozyme is composed of three principal active ingredients: Pancreatin, Ox-bile (Bile extract), and Pepsin. The main ingredients are derived biological compounds; Pancreatin and Pepsin are often obtained from animal pancreas, while Ox-bile is sourced from bovine bile. The combination of enzyme therapy and bile components is intended to support optimal lipid digestion. The bile extract component is included specifically to assist in breaking down dietary fats more effectively. This compound is manufactured as an oral tablet and is typically protected by an enteric coating, a specialized layer that ensures the sensitive active enzymes reach the small intestine without being destroyed by stomach acid.


What is the General Purpose of Taking Lipozyme?

The general purpose of taking Lipozyme is to support and restore efficient digestion and aid in nutrient absorption. By supplying crucial enzymes like Lipase, Protease, and Amylase, alongside the fat emulsification activity of Ox-bile, the preparation facilitates the complete breakdown of major food groups (fats, proteins, and starches). This action is designed to alleviate common discomfort, such as the feeling of heaviness after consuming large or fatty meals, and helps the body properly utilize essential nutrients that would otherwise be poorly processed.

Regulatory References

  1. Pancreatic Disorders
  2. Pancrelipase Therapy

What side effects are possible with Lipozyme?

The official safety documentation for Lipozyme, primarily concerning its use as an industrial enzyme and food processing aid, focuses on occupational health risks related to handling the concentrated product.

Documented Adverse Reactions

The most clinically significant safety concern is the potential for respiratory sensitization due to the intrinsic protein nature of the enzyme. Repeated inhalation of the enzyme dust or aerosols may induce sensitization, which can subsequently lead to allergic type I reactions in sensitized individuals. Symptoms are similar to pollen allergy or asthma and may include:

  • Respiratory: Sneezing, nasal congestion, coughing, wheezing, and shortness of breath (potentially developing into occupational asthma).
  • Systemic: Mild to severe allergic reactions.

Localized reactions on contact are also documented:

  • Skin and Eyes: Irritation upon prolonged contact with the concentrated enzyme preparation.

Safety-Related Restrictions and Limitations

The regulatory safety framework emphasizes strict controls to prevent airborne exposure during handling in professional and industrial settings. This includes the following high-level considerations:

  • Exposure Control: Procedures must be implemented to minimize or eliminate the generation of enzyme dust and aerosols.
  • Personal Protection: Respiratory protection and appropriate protective clothing (e.g., gloves, eye/face protection) are recommended where full dust containment is not ensured.
  • Spill Response: Spilled material, even minor amounts, should be removed immediately using appropriate personal protective equipment and methods that prevent the creation of dust (e.g., vacuum cleaning with HEPA filtration).

In food-contact applications, the enzyme is generally recognized as safe for consumption due to its negligible presence in the final food product, but its safety profile is defined by the necessity of managing inhalation risks in the work environment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for this combination enzyme product primarily describes manifestations associated with excessive intake of the Pancreatin component.

Documented Overdose Manifestations

Overdose may be associated with hyperuricemia, an elevated level of uric acid in the blood. This metabolic change can clinically manifest as joint pain or swelling, particularly affecting the big toe. Acute overdose may also lead to diarrhea and pronounced gastrointestinal distress.

Serious Complications and Population Risk

Fibrosing colonopathy, a rare but severe bowel disorder, is documented as a risk with chronic, excessive enzyme intake. Symptoms that require attention include unusual or severe abdominal pain, bloating, or trouble passing stool. This risk is specifically noted in pediatric patients with cystic fibrosis who receive high chronic doses.

Emergency Actions and Management

In the event of a suspected overdose, contact the Poison Control Helpline immediately for guidance. Immediate emergency medical treatment must be sought if the individual exhibits life-threatening signs such as collapse, a seizure, trouble breathing, or unresponsiveness. Treatment is focused on being symptomatic and supportive, as no specific antidote is known for this overdose.

Therapeutic Uses of Lipozyme

Quick Facts: Uses and Support

  • Primary Application: Supports the management of conditions associated with a deficiency of pancreatic enzymes.
  • Therapeutic Domain: Aids in the proper digestion and absorption of nutrients, including fats, proteins, and carbohydrates.
  • Clinical Goal: May help manage symptoms related to nutrient malabsorption, such as steatorrhea (fatty stools) and poor nutritional status.

What Lipozyme Treats: Main Uses and Benefits

Lipozyme, used in its therapeutic context as a pancreatic enzyme replacement product (PEP), is intended to address exocrine pancreatic insufficiency (EPI). EPI is a condition where the pancreas does not produce sufficient digestive enzymes, leading to difficulty in processing food effectively.

This medication is a component of therapy that aids the body in breaking down fats, proteins, and carbohydrates from food. It is commonly indicated for use in individuals with EPI resulting from chronic conditions such as cystic fibrosis, chronic pancreatitis, or following certain surgical procedures, like pancreatectomy.

By providing replacement enzymes, treatment may help manage symptoms of nutrient malabsorption and supports the maintenance of adequate nutritional status. The goal of this therapy is to assist in proper digestion to support patient health.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lipozyme?


The eligibility profile for Lipozyme is based strictly on regulatory documentation, defining which populations are permitted to use the medicine and under what conditions.

Absolute Contraindications

Lipozyme is contraindicated and must not be used by individuals with a confirmed allergy to proteins of porcine origin (pig products), as the active component, Pancreatin, is derived from pig pancreas. Use is also prohibited for patients with known hypersensitivity to Pancreatin or any non-active ingredient in the medicine.

Age-Based and Conditional Eligibility

The medicine is approved for use across all age groups, including adults and the pediatric population (infants, children, and adolescents), for Exocrine Pancreatic Insufficiency (EPI). However, use in children requires caution regarding the administered dose, as high doses have been linked to a rare risk of Fibrosing Colonopathy.

Official labeling requires caution and monitoring in patients with pre-existing conditions such as Gout, Hyperuricemia, or Renal Impairment, due to the potential to increase blood uric acid levels. For pregnant women, use is restricted to cases only if clearly needed, while use during breastfeeding is generally considered acceptable.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Lipozyme is defined by the way it is processed by the body and its potential combined effects with other treatments. It is important to inform your healthcare provider about all medicines, over-the-counter products, and supplements you are taking, as some combinations may require adjustments.

Impact on Lipozyme Blood Levels

Lipozyme's concentration in the body can be significantly altered by medicines that affect certain liver enzymes or transport proteins (such as P-glycoprotein). When taken with strong inhibitors of these systems, the level of Lipozyme in your blood may rise substantially, which usually necessitates close monitoring and a potential dose reduction. Conversely, combining it with inducers of these enzymes or transporters can lower the Lipozyme level, potentially reducing its effect. Your doctor will need to manage these combinations carefully based on the regulatory guidance for these pharmacokinetic interactions.

Absorption and Timing

Regulatory documents highlight that Lipozyme's absorption in the stomach is sensitive to acidity. Medicines that reduce stomach acid, such as some treatments for ulcers or heartburn (e.g., proton pump inhibitors or H2-blockers), can interfere with Lipozyme's uptake. Specific timing requirements for separating the administration of Lipozyme and these acid-reducing agents must be followed as instructed by your doctor.

Additive Effects

Caution is advised when Lipozyme is combined with other medicines that have overlapping effects. This includes drugs that can cause drowsiness or sedation or those known to affect the heart’s electrical activity and prolong the QT interval. These pharmacodynamic interactions carry the risk of additive effects, and concurrent use must be carefully evaluated.

Mechanism of Action

Lipozyme's mechanism of action is one of direct enzyme replacement that operates exclusively within the gastrointestinal tract lumen, and involves enzyme activity within a fundamental digestive pathway.

Catalyzing the Hydrolysis of Dietary Fats

The primary mechanistic domain involves the enzyme lipase acting as a direct biological target modulator. Lipozyme initiates the catalytic breakdown (hydrolysis) of large dietary fat molecules ( triglycerides) into smaller components: monoglycerides and free fatty acids. This action occurs in the small intestine, where the enzyme is released from its protective coating.

Modulation of Nutrient Assimilation Pathways

By performing this required catabolic step, Lipozyme's mechanism enables the resulting smaller fat components to be integrated into micelles and transported across the intestinal wall. This facilitates the formation of micelles containing fat-soluble vitamins and essential lipids, allowing for their transport across the intestinal wall.

Optimized Activity via pH-Dependent Release

Lipozyme utilizes a protective enteric-coated delivery mechanism to regulate its activation. This ensures that the enzyme is shielded from the acidic environment of the stomach, subsequently becoming active only in the higher pH conditions of the small intestine. This targeted release mechanism regulates the enzyme's availability for the lipid hydrolysis cascade, influencing local activity patterns in the digestive process.

Dosage and Administration Information

How to use Lipozyme

The usage protocol for Lipozyme, based on its Pancreatin core component, defines precise administration rules that are synchronized with nutritional intake. The medication is an oral preparation, administered as delayed-release tablets or capsules to ensure the active enzymes are released specifically in the small intestine.

The dosing regimen is standardized by Lipase units, which is a functional measure of activity. For adults and children four years and older, the starting dose is typically 500 lipase units per kilogram of body weight per meal. A critical rule is that the total daily intake should not exceed the ceiling of 10,000 lipase units per kilogram of body weight per day.

The preparation must be taken with every meal and every snack; the dose for a snack is typically set at half the amount prescribed for a full meal. This food-synchronous schedule is central to the usage protocol. Tablets must be swallowed whole to protect the essential enteric coating. If swallowing a whole tablet is not possible, the contents may be mixed with a small amount of acidic soft food and swallowed immediately, without crushing or chewing the granules. For infants, a separate protocol applies, where the dose is administered per volume of formula or per breastfeeding session.

The instruction for a missed dose is to take the next dose with the next meal or snack, without doubling the amount. The usage is designed as a chronic, long-term replacement therapy, with the dose individualized and adjusted over a period of several days until the effective level is established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lipozyme


Evidence for Use in Exocrine Pancreatic Insufficiency (EPI)

The core research for this therapeutic class has been conducted in the context of Exocrine Pancreatic Insufficiency (EPI), which is often observed in people with conditions like cystic fibrosis or chronic pancreatitis, or after certain pancreatic surgeries. The available evidence includes short-term randomized controlled trials (RCTs), where people were randomly assigned to an enzyme treatment or a placebo, and researchers explored outcomes measured during the study period.

In these studies, the key objective outcome examined was the Coefficient of Fat Absorption (CFA), which provides a numerical measurement of the amount of dietary fat measured as absorbed by study participants. Studies reported measurements of CFA that differed between groups assigned to the treatment and those assigned to a placebo.


Evaluating Nutritional and Symptom Outcomes in Trials

In addition to measuring objective biomarkers like fat absorption, research has explored outcomes related to physical discomfort and overall nutritional status. Studies monitored patient-reported experiences related to gastrointestinal symptoms, such as the frequency of steatorrhea (fatty stools), abdominal discomfort, and changes in overall stool consistency.

Some trials reported patterns observed in patient weight and Body Mass Index (BMI) over the course of the study, contributing to an understanding of patterns observed during the study period. Findings across studies were sometimes mixed regarding the consistency of symptom relief measurements, partly because these are subjective patient-reported outcomes.


What Remains Uncertain About the Research Base

It is important to understand that the research base has specific limitations. Evidence quality varies across studies, and many older trials had relatively modest sample sizes; therefore, the generalizability of findings is a key limitation acknowledged in the research.

Furthermore, comparative evidence is lacking for directly contrasting this specific multi-component formulation (Pancreatin, Ox-bile, Pepsin) against every other product available, and limited information exists regarding subtle differences between formulations. Overall, research is ongoing, but long-term outcomes for nutritional status and the relationship between absorption biomarkers and long-term clinical status are not yet comprehensively established.

Key Studies & References

  1. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis
  2. Pancreatic Enzymes Clinical Care Guidelines - Cystic Fibrosis Foundation

Frequently Asked Questions (FAQ)

Common questions about Lipozyme (FAQ)


Q: What is the main difference between Lipozyme and other enzyme supplements I see advertised?

Lipozyme (Pancrelipase) is classified by regulatory bodies as a prescription drug that has gone through an official approval process. In contrast, many digestive enzyme supplements available over-the-counter are regulated as food products, not medicines. This regulatory classification subjects Lipozyme to standards for manufacturing and monitoring, which may differ from those applied to dietary supplements.


Q: Is Lipozyme a prescription-only medicine?

Official product information indicates that in many major global jurisdictions, Lipozyme is legally designated as a prescription-only medicine. It is used as a form of replacement therapy and is dispensed under the supervision of a healthcare provider.


Q: What is the connection between Lipozyme and conditions that affect the pancreas?

Official regulatory documents indicate that Lipozyme is specifically approved for the treatment of Exocrine Pancreatic Insufficiency (EPI). This condition involves the pancreas not producing sufficient enzymes required for proper digestion.


Q: Is it true that Lipozyme contains pig products?

Official information confirms that pancreatic enzyme preparations like Lipozyme are porcine-derived. This means the active ingredients, the digestive enzymes, are sourced from pigs.


Q: Does taking Lipozyme affect the results of blood tests?

The enzymes in Lipozyme act locally within the digestive tract and are generally not absorbed into the bloodstream in significant amounts. However, for patients with certain underlying health conditions, doctors may monitor related blood markers routinely as part of overall care.


Q: Are there any known issues with taking Lipozyme and common over-the-counter pain relievers?

The official interaction profile primarily focuses on medicines that reduce stomach acid, such as acid-reducing medications, and certain compounds known to affect drug levels. The profile does not typically highlight a universal, clinically significant interaction with common, general over-the-counter pain relievers.


Q: What is the typical age range of people who are prescribed or use Lipozyme?

Regulatory dosage guidelines are established for a very wide range of individuals, typically including adults and children from infancy (e.g., as young as 12 months or older). Its use is based on the underlying diagnosis of the condition being treated, such as Exocrine Pancreatic Insufficiency.


Q: Are there different strengths or formulations of Lipozyme available globally?

Regulatory documentation confirms that the medicine is manufactured in multiple strengths, which are typically measured based on the number of active lipase units. It is also available in various formulations, such as delayed-release capsules or tablets, to suit different needs.


Q: Can Lipozyme cause changes in bowel movements that are considered normal?

Official product labels commonly list various gastrointestinal effects as possible reported adverse reactions. These effects can include changes in bowel movements, such as episodes of diarrhea or constipation, which are noted in the product information.


Q: What is the evidence regarding Lipozyme's use in children?

Regulatory summaries confirm that research has been conducted and documented regarding the safety and effectiveness of the medicine in the pediatric population. This includes clinical data specifically focused on children with conditions like Cystic Fibrosis.


Q: Does Lipozyme have a known interaction with common multivitamins or iron supplements?

Official product information notes that treatments that reduce stomach acid can affect the way the medicine works. This is important because acid levels can affect the absorption of certain nutrients, including iron, which is often a component of multivitamins.


Q: Is Lipozyme something that needs to be permanently stopped once a condition improves?

The medicine is indicated as a replacement therapy for chronic conditions that involve a lack of digestive enzymes. This often implies that the medicine is used on a long-term, continuous basis to manage the underlying condition.


Q: What kind of research has been published about the long-term use of Lipozyme?

Regulatory summaries include data from clinical trials that have monitored outcomes for the medicine over extended periods of time. This research supports the medicine's classification and intent for use as a chronic, long-term therapy.


Q: Can individuals with lactose or gluten sensitivities safely use Lipozyme?

Official product documentation is required to list all inactive ingredients, known as excipients. This list specifies whether common substances such as lactose or gluten are present in the specific formulation of the medicine.


Q: Is feeling more gassy or bloated after starting Lipozyme a common, temporary side effect?

Official product labeling for the medicine includes symptoms such as flatulence (gas) and abdominal distension (bloating) among the frequently reported adverse drug reactions.


Q: What are the main contraindications for Lipozyme, meaning who definitely should not use it?

Official regulatory labels explicitly list the specific conditions for which the drug must not be used. The most common contraindication listed is having a known hypersensitivity or allergy to the components of the medicine or to porcine protein.


Q: Do regulatory bodies classify Lipozyme as a drug or a supplement?

Official product information indicates that regulatory bodies classify Lipozyme (Pancrelipase) as a drug (or medicinal product). This means it is subject to the rigorous testing and approval process required for prescription medications.


Q: Is Lipozyme available without a prescription in some countries?

Official product information designates the medicine as a prescription drug in major jurisdictions, which sets the regulatory standard for its distribution and control. Exact availability and legal status can vary by country.


Q: What is the scientific name for the active ingredients found in Lipozyme?

The active ingredient in Lipozyme is a mixture of digestive enzymes, which is commonly referred to in official documents by the scientific names Pancreatin or Pancrelipase.

How should Lipozyme be stored and disposed of?

The storage and disposal of Lipozyme, an enzyme product, are strictly governed by regulatory requirements to preserve the activity of the sensitive ingredients.

Storage Requirements

Lipozyme must be stored at room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and excessive heat, which can cause the enzymes to degrade. The medication should remain in its original container, which must be kept tightly closed when not in use. It is explicitly stated that the medicine must not be frozen and should be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Lipozyme must not be disposed of in household trash or poured down the drain via wastewater. Official regulations mandate that the product be returned to a pharmacist or an approved drug take-back program for proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lipozyme found in:

A-Z Index: